SNP rs2073618 of the osteoprotegerin gene is associated with diabetic retinopathy in Slovenian patients with type 2 diabetes

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Mankoč Ramuš, Sara ^a   Kumše, Tina ^a   Globočnik Petrovič, Mojca ^b   Petrovič, Daniel ^a   Cilenšek, Ines ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OSTEOPROTEGERIN;

ADULT; AGED; ARTICLE; BIOMICROSCOPY; CASE CONTROL STUDY; CIRCULATION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETIC RETINOPATHY; DIASTOLIC BLOOD PRESSURE; FEMALE; FUNDUS CAMERA; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENOTYPE; HUMAN; INSULIN TREATMENT; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PROMOTER REGION; PROTEIN FUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SLOVENIA; SMOKING; SYSTOLIC BLOOD PRESSURE; VASCULARIZATION; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; HAPLOTYPE; MIDDLE AGED; PATHOLOGY; RISK FACTOR;

AGED; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; OSTEOPROTEGERIN; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 84887451782     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/364073     Document Type: Article

References (35)

1. Awata T., Inoue K., Kurihara S., Ohkubo T., Watanabe M., Inukai K., Inoue I., Katayama S., A common polymorphism in the 5′-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 2002 51 5 1635 1639 2-s2.0-0036316846
2. Lu Y., Shi Y., Ge Y., Yin J., Huang Z., Two polymorphisms (Rs699947, Rs2010963) in the VEGFA gene and diabetic retinopathy: an updated meta-analysis. Journal of Diabetes & Metabolism 2012 supplement 3 6
3. Treacy M. P., Hurst T. P., The case for intraocular delivery of PPAR agonists in the treatment of diabetic retinopathy. BMC Ophthalmology 2012 12, article 46
4. Knudsen S. T., Foss C. H., Poulsen P. L., Andersen N. H., Mogensen C. E., Rasmussen L. M., Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular with microvascular complications. European Journal of Endocrinology 2003 149 1 39 42 2-s2.0-0038825591
5. Jørgensen G. M., Vind B., Nybo M., Rasmussen L. M., Højlund K., Acute hyperinsulinemia decreases plasma osteoprotegerin with diminished effect in type 2 diabetes and obesity. European Journal of Endocrinology 2009 161 1 95 101 2-s2.0-67650709484 10.1530/EJE-09-0141
6. Rasmussen L. M., Tarnow L., Hansen T. K., Parving H.-H., Flyvbjerg A., Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular mordibity in type 1 diabetic patients. European Journal of Endocrinology 2006 154 1 75 81 2-s2.0-32844472729 10.1530/eje.1.02049
7. Lieb W., Gona P., Larson M. G., Massaro J. M., Lipinska I., Keaney J. F., Rong J., Corey D., Hoffmann U., Fox C. S., Vasan R. S., Benjamin E. J., Odonnell C. J., Kathiresan S., Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortality. Arteriosclerosis, Thrombosis, and Vascular Biology 2010 30 9 1849 1854 2-s2.0-77955983144 10.1161/ATVBAHA.109.199661
8. Zhang J., Fu M., Myles D., Zhu X., Du J., Cao X., Chen Y. E., PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways. FEBS Letters 2002 521 1-3 180 184 2-s2.0-0037134852 10.1016/S0014-5793(02)02872-7
9. Hofbauer L. C., Heufelder A. E., Clinical review 114-Hot topic: the role of receptor activator of nuclear factor- B ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases. Journal of Clinical Endocrinology and Metabolism 2000 85 7 2355 2363 2-s2.0-0034455667 10.1210/jc.85.7.2355
10. Wuyts W., Van Wesenbeeck L., Morales-Piga A., Ralston S., Hocking L., Vanhoenacker F., Westhovens R., Verbruggen L., Anderson D., Hughes A., Van Hul W., Evaluation of the role of RANK and OPG genes in Paget's disease of bone. Bone 2001 28 1 104 107 2-s2.0-0035142846 10.1016/S8756-3282(00)00411-7
11. Alvarez L., Peris P., Guañabens N., Vidal S., Ros I., Pons F., Filella X., Monegal A., Muñoz-Gomez J., Ballesta A. M., Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates. Arthritis & Rheumatism 2003 48 3 824 828 2-s2.0-0037334534 10.1002/art.10834
12. Hofbauer L. C., Schoppet M., Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. The Journal of the American Medical Association 2004 292 4 490 495 2-s2.0-3242781731 10.1001/jama.292.4.490
13. Kiechl S., Schett G., Wenning G., Redlich K., Oberhollenzer M., Mayr A., Santer P., Smolen J., Poewe W., Willeit J., Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004 109 18 2175 2180 2-s2.0-2442492972 10.1161/01.CIR.0000127957.43874.BB
14. Ziegler S., Kudlacek S., Luger A., Minar E., Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease. Atherosclerosis 2005 182 1 175 180 2-s2.0-23944444764 10.1016/j.atherosclerosis. 2005.01.042
15. Papadopouli A. E., Klonaris C. N., Theocharis S. E., Role of OPG/RANKL/RANK axis on the vasculature. Histology and Histopathology 2008 23 4-6 497 506 2-s2.0-42349095974
16. Avignon A., Sultan A., Piot C., Elaerts S., Cristol J. P., Dupuy A. M., Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients. Diabetes Care 2005 28 9 2176 2180 2-s2.0-24144488713 10.2337/diacare.28.9.2176
17. Olesen P., Ledet T., Rasmussen L. M., Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF- Diabetologia 2005 48 3 561 568 2-s2.0-16844385959 10.1007/s00125-004-1652-8
18. Jang Y. S., Young G. S., Choon H. C., Elevated serum osteoprotegerin levels are associated with vascular endothelial dysfunction in type 2 diabetes. Diabetes Care 2006 29 7 1664 1666 2-s2.0-33746445963 10.2337/dc06-0631
19. Singh D. K., Winocour P., Farrington K., Endothelial cell dysfunction, medial arterial calcification and osteoprotegerin in diabetes. British Journal of Diabetes and Vascular Disease 2010 10 2 71 77 2-s2.0-77952493593 10.1177/1474651409355453
20. Jeffcoate W., Vascular calcification and osteolysis in diabetic neuropathy-is RANK-L the missing link? Diabetologia 2004 47 9 1488 1492 2-s2.0-5644297239 10.1007/s00125-004-1477-5
21. Grauslund J., Rasmussen L. M., Green A., Sjølie A. K., Does osteoprotegerin relate to micro- and macrovascular complications in long-term type 1 diabetes? Scandinavian Journal of Clinical and Laboratory Investigation 2010 70 3 188 193 2-s2.0-77951429703 10.3109/00365511003653599
22. Kahn R., Expert Commitee on the Diagnosis and Classification of Diabetes Mellitus, Follow up report on the diagnosis of diabetes mellitus. Diabetes Care 2003 26 11 3160 3167 2-s2.0-0242300698 10.2337/diacare.26.11.3160
23. Early Treatment Diabetic Retinopathy Study Research Group, Grading diabetic retinopathy from stereoscopic color fundus photographs-an extension of the modified Airlie House classification ETDRS report number 10. Ophthalmology 1991 98 supplement 5 786 806
24. Pitocco D., Zelano G., Gioffrè G., Di Stasio E., Zaccardi F., Martini F., Musella T., Scavone G., Galli M., Caputo S., Mancini L., Ghirlanda G., Association between osteoprotegerin G1181C and T245G polymorphisms and diabetic charcot neuroarthropathy: a case-control study. Diabetes Care 2009 32 9 1694 1697 2-s2.0-69549105887 10.2337/dc09-0243
25. Elston R. C., Forthofer R., Testing for Hardy-Weinberg equilibrium in small samples. Biometrics 1977 33 3 536 542 2-s2.0-0017659970
26. The 1000 Genomes Project. http://www.1000genomes.org/
27. Biscetti F., Straface G., Giovannini S., Association between TNFRSF11B gene polymorphisms and history of ischemic stroke in Italian diabetic patients. Human Genetics 2013 132 1 49 55
28. Nehring P., Mrozikiewicz-Rakowska B., Sobczyk-Kopcioł A., Osteoprotegerin gene rs2073617 and rs3134069 polymorphisms in type 2 diabetes patients and sex-specific rs2073618 polymorphism as a risk factor for diabetic foot. Polish Archives of Internal Medicine 2013 123 4 176 182
29. Korzon-Burakowska A., Jakóbkiewicz-Banecka J., Fiedosiuk A., Osteoprotegerin gene polymorphism in diabetic Charcot neuroarthropathy. Diabetic Medicine 2012 29 6 771 775
30. Van Campenhout A., Golledge J., Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis 2009 204 2 321 329 2-s2.0-67349099856 10.1016/j.atherosclerosis.2008.09.033
31. Chang Y.-H., Lin K.-D., He S.-R., Hsieh M.-C., Hsiao J.-Y., Shin S.-J., Serum osteoprotegerin and tumor necrosis factor related apoptosis inducing-ligand (TRAIL) are elevated in type 2 diabetic patients with albuminuria and serum osteoprotegerin is independently associated with the severity of diabetic nephropathy. Metabolism 2011 60 8 1064 1069 2-s2.0-79960556004 10.1016/j.metabol.2010.11.002
32. Secchiero P., Corallini F., Pandolfi A., Consoli A., Candido R., Fabris B., Celeghini C., Capitani S., Zauli G., An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction. American Journal of Pathology 2006 169 6 2236 2244 2-s2.0-34447624317 10.2353/ajpath.2006.060398
33. Graves D. T., Kayal R. A., Diabetic complications and dysregulated innate immunity. Frontiers in Bioscience 2008 13 4 1227 1239 2-s2.0-38449089938 10.2741/2757
34. Kim H.-H., Shin H. S., Kwak H. J., Ahn K. Y., Kim J.-H., Lee H. J., Lee M.-S., Lee Z. H., Koh G. Y., RANKL regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. The FASEB Journal 2003 17 14 2163 2165 2-s2.0-0642364978
35. Stehouwer C. D. A., Lambert J., Donker A. J. M., Van Hinsbergh V. W. M., Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovascular Research 1997 34 1 55 68 2-s2.0-0030976646 10.1016/S0008-6363(96)00272-6